Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
The receipt of this order further strengthens the company's position in the global pharmaceutical market
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
Subscribe To Our Newsletter & Stay Updated